For acute patients hospitalized for a clinical disease (e.g.: heart failure), indicating rivaroxaban for 6.5 weeks after discharge did not significantly reduce the risk of symptomatic venous thromboembolism. Efficacy primary end point rate was low, with 0.83% in patients treated with rivaroxaban vs 1.1% of patients receiving placebo. This work presented at ESC and…
ESC 2018 | FUTURE: A Thorn in FFR and More Questions than Answers
As observed at the preliminary analysis that motivated the FUTURE trial early termination, the use of fractional flow reserve (FFR) to guide revascularization in an unselected population with multivessel disease was associated to twice the mortality rate in one year, with no beneficial impact on other end points. Even though the combined end point of…
ESC 2018 | FRANCE-TAVI: Atrial Fibrillation and Anticoagulation Associated to Mortality in TAVR
Some of the many ongoing randomized studies including patients with atrial fibrillation (AF) might finally answer the question on the best antithrombotic scheme post TAVR. According to this registry, in patients undergoing transcatheter aortic valve replacement, independent predictors of death at 3 years are being a man, having moderate to severe kidney failure, and having…
Frailty and Critical Limb ischemia: Facing a New Challenge
Courtesy of Dr. Carlos Fava. Critical limb ischemia is the final stage of peripheral vascular disease and is associated to pain at rest, trophic lesions, and gangrene. It is also associated to amputation and reduced mobility. When it happens in frail patients, it presents a challenge. This population is on the rise and there is…
SOLACI-SOCIME 2018 | Endovascular Treatment of Mesenteric Artery Disease
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Christopher White, entitled “Endovascular Treatment of Mesenteric Artery Disease”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI-SOCIME 2018 | Retrograde approach: techniques and results
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Saeko Takahashi, entitled “Retrograde approach: techniques and results ”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI-SOCIME 2018 | New Indications
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Flavio Ribichini, entitled “New Indications”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI-SOCIME 2018 | When Not to Use a Device: Characteristics of Atrial Septal Defects that Do Not Lead to Percutaneous Closure
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. In this case see the presentation of Dr. Lee Benson, entitled “When Not to Use a Device: Characteristics of Atrial Septal Defects that Do Not Lead to Percutaneous Closure”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc.,…
What Happens with Small Dissections and Imperfections Only Shown by OCT?
When we carry out an angioplasty guided by angiography alone, as we historically have, we are almost blind. Nowadays, optical coherence tomography (OCT) offers plenty of detail but also raises costs, procedure time, and contrast volume. The question that this study aimed to answer is whether becoming aware of all small defects and imperfections in…
Balloon Mitral Valvuloplasty at Very Long Term
With a mean follow up of 15 years, and some patients that survived over 20 years, this study shows that more than 75% of patients with rheumatic mitral stenosis show sustained results with balloon valvuloplasty. Predictors of this excellent long-term outcome are many, but they are determined mainly by age, prior symptoms and valve area…